戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 standard for the treatment of PCO (Posterior Capsule Opacification).
2 macular oedema (CMO), cataract and posterior capsule opacification.
3 xis-IOL overlap, capsular folds, or anterior capsule opacification.
4 d macular oedema, glare, halos and posterior capsule opacification.
5 ve capsular bend as a deterrent to posterior capsule opacification.
6 sm for the aberrant cell growth in posterior capsule opacification.
7 spikes, cystoid macular edema, and posterior capsule opacification.
8 be important in the development of posterior capsule opacification.
9 for use in longitudinal studies of posterior capsule opacification.
10  al. for precise quantification of posterior-capsule opacification.
11  may be effective in prevention of posterior capsule opacification.
12 ective measure in the treatment of posterior capsule opacification.
13 cataracts (3.6%), intraocular lens posterior capsule opacification (1.8%) and a posterior chamber int
14 stoperative complications included posterior capsule opacification (50.9%), posterior synechiae (21.7
15 ble in prevention and treatment of posterior capsule opacification, a dreaded complication of catarac
16 een piggyback intraocular lenses), posterior capsule opacification and lens epithelial cell ongrowth.
17 acologic methods); 2) treatment of posterior capsule opacification; and 3) characteristics of the cap
18 ant an intraocular lens will be to posterior capsule opacification as a consequence of regenerating c
19 harp optic edges markedly decrease posterior capsule opacification as compared with round-edged impla
20                                    Posterior-capsule opacification, by far the most common complicati
21 er rates of clinically significant posterior capsule opacification compared to treatment with NSAIDs
22                                    Posterior capsule opacification developed in 11 eyes (57.9%), 9 ey
23                                    Posterior capsule opacification developed in 14 eyes (34.2%); 12 e
24                      Evaluation of Posterior Capsule Opacification (EPCO) image analysis software was
25 roillumination using evaluation of posterior capsule opacification (EPCO) software.
26 effective cleanup, there is reduced anterior capsule opacification, fibrosis, and decentration of the
27 ual acuity (CDVA), IOL centration, posterior capsule opacification, glaucoma, and retinal complicatio
28 ency and were found in 60.4%, with posterior capsule opacification in 29.6% and posterior capsule rup
29 rest are techniques for inhibiting posterior capsule opacification in pediatric patients by optic cap
30 psulorhexis is required to inhibit posterior-capsule opacification in pediatric patients; work by Nis
31 , which may decrease resistance to posterior capsule opacification in the face of a regenerating cort
32  result in different entities, e.g. anterior capsule opacification, interlenticular opacification (be
33                                    Posterior capsule opacification is a frequent postoperative proble
34                                    Posterior capsule opacification is also potentially solvable with
35                                    Posterior capsule opacification is an ongoing cellular redistribut
36                                    Posterior capsule opacification is the most frequent late complica
37                                    Posterior capsule opacification occurred in 66 eyes (82.5%), and 4
38  in the percentage area covered by posterior capsule opacification over time.
39 her rates of hypotony (p = 0.043), posterior capsule opacification (p = 0.047), and surgically induce
40  n = 2 studies, 161 participants), posterior capsule opacification (P = 0.46; I(2) = 0%; n = 2 studie
41 n about the long-term incidence of posterior capsule opacification (PCO) after cataract surgery in pa
42                                    Posterior capsule opacification (PCO) after cataract surgery is in
43 o objectively assess the long-term posterior capsule opacification (PCO) and neodymium-doped yttrium
44                                    Posterior capsule opacification (PCO) arises because of a persiste
45  in intraocular lens (IOL) design, posterior capsule opacification (PCO) arising from lens cell growt
46         The fibrotic lens disorder posterior capsule opacification (PCO) develops in millions of pati
47 usceptibility to calcification and posterior capsule opacification (PCO) formation.
48 his resilient growth gives rise to posterior capsule opacification (PCO) in a significant proportion
49 on of After-Cataract [AQUA II]) of posterior capsule opacification (PCO) in high-resolution digital r
50                                    Posterior capsule opacification (PCO) is a complication of catarac
51                                    Posterior capsule opacification (PCO) is the most common complicat
52                                    Posterior capsule opacification (PCO) is the most common post-oper
53  is common, routine and effective, posterior capsule opacification (PCO) occurs in 30-50% of patients
54 dually develop the complication of posterior capsule opacification (PCO) or secondary cataract.
55  determine the 5-year incidence of posterior capsule opacification (PCO) requiring Nd:YAG laser capsu
56 dophakic patients with symptomatic posterior capsule opacification (PCO) underwent Nd:YAG laser capsu
57 ective refraction, IOL centration, posterior capsule opacification (PCO), and investigators' satisfac
58 um aluminum garnet capsulotomy for posterior capsule opacification (PCO), and visual acuity (VA) in e
59 a wound-healing response, known as posterior capsule opacification (PCO), following cataract surgery.
60 We describe a patient with massive posterior capsule opacification (PCO), i.e. Elschnig's Pearls (EP)
61 using an in vitro culture model of posterior capsule opacification (PCO).
62 ar migration, thus contributing to posterior capsule opacification (PCO).
63 eta2 antibody in a rodent model of posterior capsule opacification (PCO).
64 omplication of cataract surgery is posterior capsule opacification (PCO; secondary cataract).
65 ental in reducing the incidence of posterior capsule opacification, (PCO, secondary cataract) and hen
66 his can cause blindness because of posterior capsule opacification, proliferative vitroretinopathy, f
67 ing for a more rapid assessment of posterior capsule opacification resistance.
68 appreciably improves resistance to posterior capsule opacification, significant factors remain under
69 alyzed for PCO using Evaluation of Posterior Capsule Opacification software.
70  review addresses 1) inhibition of posterior capsule opacification (surgical techniques, intraocular
71 s exchange suggest higher rates of posterior capsule opacification than with standard cataract surger
72      In 25% of pseudophakic cases, posterior capsule opacification was noted.
73 le width in pseudophakic eyes with posterior capsule opacification were measured with anterior segmen